Search research articles
Contact Us
Filters
Showing results (691-700 of 706) with videos related to
Page
of 71
Sort By:
JACC. Heart Failure
|
August 9, 2023
Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF
Bertram Pitt, Deepak L Bhatt, Michael Szarek, et al.
Journal of the American Society of Nephrology : JASN
|
May 2, 2020
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial
Meg J Jardine, Zien Zhou, Kenneth W Mahaffey, et al.
European Heart Journal
|
October 28, 2022
Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis
Eri Toda Kato, David A Morrow, Jianping Guo, et al.
European Heart Journal
|
August 18, 2022
A polygenic risk score predicts atrial fibrillation in cardiovascular disease
Nicholas A Marston, Amanda C Garfinkel, Frederick K Kamanu, et al.
JAMA
|
March 17, 2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial
Matthew J Price, Peter B Berger, Paul S Teirstein, et al.
The New England Journal of Medicine
|
November 17, 2020
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
Deepak L Bhatt, Michael Szarek, Bertram Pitt, et al.
The New England Journal of Medicine
|
April 17, 2019
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic, Meg J Jardine, Bruce Neal, et al.
Circulation
|
July 12, 2019
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups
Kenneth W Mahaffey, Meg J Jardine, Severine Bompoint, et al.
The Lancet. Diabetes & Endocrinology
|
February 17, 2025
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial
Rahul Aggarwal, Deepak L Bhatt, Michael Szarek, et al.
JAMA
|
November 4, 2004
Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative
Deepak L Bhatt, Matthew T Roe, Eric D Peterson, et al.
Page
of 71
Search research articles
Search
Showing results (691-700 of 706) with videos related to
Sort By:
Page
of 71
JACC. Heart Failure
|
August 9, 2023
Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF
Bertram Pitt, Deepak L Bhatt, Michael Szarek, et al.
Journal of the American Society of Nephrology : JASN
|
May 2, 2020
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial
Meg J Jardine, Zien Zhou, Kenneth W Mahaffey, et al.
European Heart Journal
|
October 28, 2022
Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis
Eri Toda Kato, David A Morrow, Jianping Guo, et al.
European Heart Journal
|
August 18, 2022
A polygenic risk score predicts atrial fibrillation in cardiovascular disease
Nicholas A Marston, Amanda C Garfinkel, Frederick K Kamanu, et al.
JAMA
|
March 17, 2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial
Matthew J Price, Peter B Berger, Paul S Teirstein, et al.
The New England Journal of Medicine
|
November 17, 2020
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
Deepak L Bhatt, Michael Szarek, Bertram Pitt, et al.
The New England Journal of Medicine
|
April 17, 2019
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic, Meg J Jardine, Bruce Neal, et al.
Circulation
|
July 12, 2019
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups
Kenneth W Mahaffey, Meg J Jardine, Severine Bompoint, et al.
The Lancet. Diabetes & Endocrinology
|
February 17, 2025
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial
Rahul Aggarwal, Deepak L Bhatt, Michael Szarek, et al.
JAMA
|
November 4, 2004
Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative
Deepak L Bhatt, Matthew T Roe, Eric D Peterson, et al.
Page
of 71